Essential Thrombocythemia (ET) is the Primary Hematologic Condition Presenting with Thrombocytosis
Essential thrombocythemia is the most common primary hematologic condition presenting with sustained thrombocytosis (platelet count ≥450 × 10⁹/L), though secondary causes account for the majority (83%) of all thrombocytosis cases. 1, 2, 3
Differential Diagnosis Framework
When evaluating thrombocytosis, you must systematically distinguish between:
Primary (Clonal) Causes
- Essential thrombocythemia - most common primary cause
- Polycythemia vera (PV)
- Primary myelofibrosis (PMF), including prefibrotic PMF
- Chronic myeloid leukemia (CML) - rare presentation 4
- Myelodysplastic syndromes with ring sideroblasts and thrombocytosis
Secondary (Reactive) Causes
The most frequent secondary causes are 3:
- Tissue injury (32.2%)
- Infection (17.1%)
- Chronic inflammatory disorders (11.7%)
- Iron deficiency anemia (11.1%)
- Malignancy
- Post-splenectomy state
Diagnostic Approach to Essential Thrombocythemia
The diagnosis of ET requires meeting all four WHO criteria 1:
Sustained platelet count ≥450 × 10⁹/L (lowered from the previous 600 × 10⁹/L threshold to improve early detection)
Bone marrow biopsy showing:
- Proliferation mainly of megakaryocytic lineage
- Increased numbers of enlarged, mature megakaryocytes in loose clusters
- No significant increase or left-shift of neutrophil granulopoiesis or erythropoiesis
- Minimal or absent reticulin fibrosis
Exclusion of other WHO-defined myeloid neoplasms:
- Not meeting criteria for PV, PMF, CML, or MDS
- Critical pitfall: Must exclude occult PV in iron-deficient patients through iron replacement trial 1
- Must exclude prefibrotic PMF through careful bone marrow histologic assessment
Demonstration of clonality:
- JAK2V617F mutation (present in ~50% of ET patients) 1
- OR CALR mutation
- OR MPL mutation
- OR another clonal marker
- OR in mutation-negative patients, absence of evidence for reactive thrombocytosis
Molecular Testing Strategy
Approximately 80% of ET patients express driver mutations in a mutually exclusive manner 2:
- JAK2V617F - ~50-60%
- CALR - ~20-25%
- MPL - ~3-5%
- Triple-negative - ~10-15%
Testing sequence: Start with JAK2V617F; if negative, proceed to CALR and MPL testing 5. Additional mutations found in ~50% include TET2 (9-11%), ASXL1 (7-20%), DNMT3A (7%), and SF3B1 (5%) 2.
Clinical Significance and Risk Stratification
Primary thrombocytosis carries significantly higher thrombotic risk than secondary thrombocytosis 3. The median platelet count is higher in primary versus secondary causes.
Thrombotic Risk Stratification (IPSET Criteria) 6
Calculate risk score based on:
- Age >60 years: 1 point
- Cardiovascular risk factors: 1 point
- Previous thrombosis: 2 points
- JAK2V617F mutation: 2 points
Risk categories:
- Low risk: Score 0-1
- Intermediate risk: Score 2
- High risk: Score ≥3
Refined Risk Categories 2, 5
- Very low: Age ≤60 years, no thrombosis history, JAK2 wild-type
- Low: Same as very low but JAK2 mutation present
- Intermediate: Age >60 years with JAK2 wild-type
- High: Thrombosis history OR age >60 years with JAK2 mutation
Prognostic Implications
Life expectancy is reduced compared to the general population. Median survival is approximately 18 years overall but exceeds 35 years in younger patients 2.
Key prognostic mutations:
- MPL and CALR-1: Increased risk of myelofibrosis transformation
- Spliceosome mutations: Inferior overall and MF-free survival
- TP53: Leukemic transformation risk
- JAK2V617F: Associated with thrombosis risk
Leukemic transformation rate at 10 years is <1% but may be higher with JAK2 mutation plus extreme thrombocytosis or abnormal karyotype 2.
Common Diagnostic Pitfalls
- Missing occult PV: Always perform iron replacement trial in iron-deficient patients before excluding PV 1
- Overlooking prefibrotic PMF: Requires expert bone marrow histology review - prefibrotic PMF has different prognosis and management
- Assuming reactive cause without confirmation: In JAK2-negative patients with normal bone marrow, must rigorously exclude all reactive causes 1
- Using outdated platelet threshold: The current threshold is ≥450 × 10⁹/L, not 600 × 10⁹/L 1, 5